The laboratory-confirmed incident cases of invasive meningococcal disease (IMD) are expected to shrink to 3,169 cases in 2025 compared to 4,153 cases in 2015, indicating a negative annual growth rate of 2.37%, according to a report by GlobalData.
Titled ‘EpiCast Report: Meningococcal Disease – Epidemiology Forecast to 2025‘, the report mentions that among the eight major markets including US, France, Germany, Italy, Spain, UK, Brazil and Japan, the share of the five European countries in laboratory-confirmed incident cases of IMD will increase to 59.58% in 2025, compared to 45.32% in 2015.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Brazil is expected to have the highest number of laboratory-confirmed incident cases of IMD during the forecast period.
Invasive meningococcal disease is a serious infection caused by the bacterium Neisseria meningitidis (N. meningitidis). The condition is life-threatening and communicable and can result in meningitis, septicaemia, or both.
Among the laboratory-confirmed incident cases of IMD in 2015, 43.37% of the cases were serogroup C disease, while 36.46% were serogroup B disease and 5.25% were serogroup Y disease. The remaining 14.98% were attributed to other serogroups combined.
According to the report, 10.86% of laboratory-confirmed incident cases of IMD in 2015 occurred in a demography of less than one year across the major markets.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
